Kissei Pharmaceutical Co., Ltd.
Excerpts from the Second Quarter (Interim) Financial Summary: “Overview of Business Results for the Interim Period”
Pharmaceutical segment interim sales were 37,401 million yen (YoY -2.5%). While Tabneos sales declined, growth of Beova, Korsba, Tabalis, Ixelti and expanded co-promotion expenses helped maintain a certain sales mix. Overseas license income decreased. Overall sales fell short of initial forecasts. Operating income and ordinary income returned to profit, but interim net income attributable to owners of parent decreased due to special losses related to Tabneos.
Key Figures
- Net sales: 45,503 million yen
- Pharmaceutical segment net sales: 37,401 million yen
- Interim net income attributable to owners of parent: 5,191 million yen
AI要約
Overview of Results
Net sales for the interim period were 45,503 million yen (YoY -0.7%), and the pharmaceutical segment recorded 37,401 million yen (YoY -2.5%), showing a slowdown. Flagship product Tabneos posted decreased sales, while products such as Beova, Korsba, Tabalis and Ixelti showed growth. Decreases in export and technical fee revenues also had an impact. On the profit side, operating income was 1,694 million yen and ordinary income was 2,923 million yen, maintaining a return to profitability; however, interim net income was 5,191 million yen, down year-on-year due to the recording of special losses. A decline in overseas license income also contributed.
Outlook and Key Points
Based on interim results, full-year outlook remains cautious, but the progress of domestic and international new drug development and responses related to safety are expected to affect future profitability. The trajectory of new drugs such as Ixelti (original product), the market approval process for Tabneos, and development status of products for overseas launch are key points to watch.
Kissei Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
